Richard I. Steinhart, Chief Financial Officer at BioXcel Therapeutics, Inc. (BTAI), sold 372 shares at $1.26 ($469) on 2024-06-17, disclosed to the SEC on 2024-06-18.
Scheduled sale ($469) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $246 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |